{
    "clinical_study": {
        "@rank": "164787", 
        "arm_group": [
            {
                "arm_group_label": "Sodium Alginate Double Action Tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose"
            }, 
            {
                "arm_group_label": "Placebo tablets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of 4 Placebo tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to assess the effectiveness of the Compound Sodium Alginate\n      Double Action Chewable Tablets compared to placebo on acidic reflux events into the\n      esophagus in patients diagnosed with Gastroesophageal Reflux Disease (GERD)."
        }, 
        "brief_title": "Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Gastroesophageal Reflux Disease", 
        "condition_browse": {
            "mesh_term": "Gastroesophageal Reflux"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  meets the diagnostic criteria for GERD with a GERD history of frequent episodes of\n             GERD-related symptoms during the last 2 months prior to study screening.  The patient\n             must also meet the following criteria:\n\n               1. The only or main symptom is heartburn (burning feeling back of breast bone)\n                  and/or acid reflux. Symptoms persists or have occurred repeatedly for more than\n                  2 months;\n\n               2. As assessed by the Investigator at screening by questioning of the patient, the\n                  frequency of occurrence of heartburn is \u2265 3 days/week and the score of severity\n                  of heartburn in general is \u2265 moderate within 3 weeks before screening\n\n        Exclusion Criteria:\n\n          -  Patients who have a history of drug, solvent or alcohol abuse (weekly alcohol intake\n             \u2265 140g).\n\n          -  Patients who have suffered cardiac chest pain within the last year.\n\n          -  Patients who have suffered a recent, significant unexplained weight loss of more than\n             6 Kg in the last 6 months.\n\n          -  Female patients of childbearing potential who, for the duration of the study, are\n             either unwilling or unable to take adequate contraceptive precautions or are\n             unwilling to be sexually abstinent.\n\n          -  Pregnancy or lactating mother.\n\n          -  Patients with a history and/or symptom profile suggestive of the following:  any\n             other gastrointestinal (GI) disease, erosive GERD (Los Angeles [LA] classification\n             grades C-D), Barrett's esophagus, acute peptic ulcer and/or ulcer complications,\n             Zollinger-Ellison syndrome, gastric carcinoma, pyloric stenosis, oesophageal or\n             gastric surgery, intestinal obstruction, current pernicious anaemia, indication for\n             H-pylori eradication therapy, known gastro-intestinal bleeding (hematochezia or\n             hematemesis) within the last 3 months, and severe diseases of other major body\n             systems.\n\n          -  Patients who are observed at screening to have a hiatus hernia with a diameter which\n             exceeds 3cm.\n\n          -  Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines for\n             treating gastrointestinal disease, ulcerlmin or misoprostol preparations within 7\n             days prior to screening or throughout the study.\n\n          -  Patients who have taken PPIs during the 10 days prior to screening, prokinetics or H2\n             antagonists during the 5 days prior to screening or systemic glucocorticosteroids,\n             non-steroidal anti-inflammatory drugs (NSAIDs, except for low dose aspirin which can\n             be given for cardioprotection) on more than 3 consecutive days or PPI-based triple or\n             quadruple therapy for eradication of H-pylori during the last 28 days.\n\n          -  Patients taking or requiring to take macrolide antibiotics, such as erythromycin,\n             azithromycin, from the day before screening.\n\n          -  Patients with difficulty in swallowing.\n\n          -  Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia.\n\n          -  Patients with severe constipation, or history of intestinal obstruction.\n\n          -  In the opinion of the Investigator, patients with damaged heart or kidney function\n             and patients who require a low sodium diet."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872897", 
            "org_study_id": "GA1202"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sodium Alginate Double Action Tablets", 
                "description": "Four tablets as a single dose", 
                "intervention_name": "Sodium Alginate Double Action Tablets", 
                "intervention_type": "Drug", 
                "other_name": "Gaviscon Double Action Tablets"
            }, 
            {
                "arm_group_label": "Placebo tablets", 
                "description": "4 tablets as a single dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alginic acid", 
                "Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastroesophageal Reflux Disease", 
            "GERD", 
            "Acid reflux", 
            "Compound Sodium Alginate Double Action Chewable Tablet", 
            "Gaviscon Double Action Tablets"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }, 
                "name": "RB Investigational Sites"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-centred, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Double Action Tablets or Placebo Tablets", 
        "overall_official": {
            "affiliation": "Shanghai Jiatong University, School of Medicine, Shanghai, China", 
            "last_name": "Yuan Yaozong, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint will be the percentage of time during the 4 hour post dosing period with pH below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo.", 
            "measure": "Percentage of time during the 4 hour post dosing period with pH below pH 4", 
            "safety_issue": "No", 
            "time_frame": "0 to 4 hours post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872897"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of time during the 4 hour post dosing period with pH below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "Percentage of time during the 4 hour post dosing period with pH below pH 5", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 hours post-dose"
            }, 
            {
                "description": "Number of occasions during the 4 hour post dosing period when pH falls below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "Number of occasions during the 4 hour post dosing period when pH falls below pH 4", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 hours post-dose"
            }, 
            {
                "description": "Number of reflux episodes during the 4 hour post dosing period with pH below pH 4 for at least 5 minutes for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "Number of reflux episodes during the 4 hour post dosing period with pH below pH 4 for at least 5 minutes", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 hours post-dose"
            }, 
            {
                "description": "Percentage of time during the first hour post dosing with pH below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "Percentage of time during the first hour post dosing with pH below pH 4", 
                "safety_issue": "No", 
                "time_frame": "0 to 1 hour post-dose"
            }, 
            {
                "description": "Percentage of time during the first hour post dosing with pH below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "Percentage of time during the first hour post dosing with pH below pH 5", 
                "safety_issue": "No", 
                "time_frame": "0 to 1 hour post-dose"
            }, 
            {
                "description": "Number of occasions during the first hour post dosing when pH falls below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "Number of occasions during the first hour post dosing when pH falls below pH 4", 
                "safety_issue": "No", 
                "time_frame": "0 to 1 hour post-dose"
            }, 
            {
                "description": "Number of occasions during the first hour post dosing when pH falls below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "Number of occasions during the first hour post dosing when pH falls below pH 5", 
                "safety_issue": "No", 
                "time_frame": "0 to 1 hour post-dose"
            }, 
            {
                "description": "The longest reflux time during the 4 hour post dosing period (i.e. the longest period with pH below pH 4) for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "The longest reflux time during the 4 hour post dosing period (i.e. the longest period with pH below pH 4)", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 hours post-dose"
            }, 
            {
                "description": "The DeMeester scores during the 4 hour post dosing period for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets", 
                "measure": "The DeMeester scores during the 4 hour post dosing period", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 hours post-dose"
            }
        ], 
        "source": "Reckitt Benckiser Healthcare (UK) Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reckitt Benckiser Healthcare (UK) Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}